Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Cancer Trials Ireland"
Count: 82
Selected: 0
| NCT ID | Title |
|---|
| NCT03698201 | Blood Biomarker Signature in Glioma | ||
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma | ||
| NCT06024824 | Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) | ||
| NCT05518110 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer | ||
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | ||
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. | ||
| NCT03153280 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer | ||
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | ||
| NCT03162003 | Irish Programme for Stratified Prostate Cancer Therapy | ||
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | ||
| NCT02225704 | Radium-223 in Combination With Enzalutamide | ||
| NCT02160353 | Neo-adjuvant Abiraterone Prostate Study | ||
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer | ||
| NCT02050997 | Plasma Biomarkers P-DAC, V1 | ||
| NCT02050750 | TAILORx Tissue Bank | ||
| NCT02050737 | Plasma Biomarkers C-RAC, ICORG 12-27, V1 | ||
| NCT01840293 | Breast Cancer Proteomics and Molecular Heterogeneity | ||
| NCT01822444 | ANGIOPREDICT. ICORG 12-16, V3 | ||
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | ||
| NCT01722851 | Circulating miRNAs. | ||
| NCT01526369 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer | ||
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | ||
| NCT00951535 | A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17 | ||
| NCT00812669 | CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | ||
| NCT00802711 | 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer | ||
| NCT01726322 | Ovarian Reserve in Premenopausal Breast Cancer | ||
| NCT01722890 | CharactHer. ICORG 12-09, V3 | ||
| NCT04667663 | CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. | ||
| NCT03699111 | Identification of New Patient Stratification Tools in MSS RAS mt mCRC | ||
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | ||
| NCT02705859 | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) | ||
| NCT04375904 | 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) | ||
| NCT03843346 | The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer | ||
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | ||
| NCT04617067 | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | ||
| NCT01840306 | Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer | ||
| NCT00955435 | Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15 | ||
| NCT02177110 | A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma | ||
| NCT01160705 | Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2 | ||
| NCT04581070 | The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic" | ||
| NCT02219178 | Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | ||
| NCT00911716 | TC Avastin. ICORG 08-10, V6 | ||
| NCT00974168 | Spinal Cord Compression Re-Treat Study | ||
| NCT01485926 | A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. | ||
| NCT00809211 | Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | ||
| NCT02836392 | CRQ Survey Study: Clinical Research Questionnaire of Oncology Patients - A Nationwide Survey | ||
| NCT00974610 | Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. | ||
| NCT00958321 | Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35 | ||
| NCT01176487 | Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34 | ||
| NCT00955175 | Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09 |
